Blood labs are drawn on our patients so that we may monitor their progress from when they start our program to when they leave and beyond. It is a very important tool in the Doctor’s toolbox. Lab findings will show where areas are below normal and/or high. With these results, decisions can be made to alter treatment protocol for each individual’s needs.
Blood is drawn weekly under normal circumstances. They most frequently consist of a CBC (complete blood count) and a CMP ( complete metabolic panel).
The CBC checks things like white blood cell count, red blood cell count, hemoglobin, hematocrit, and the ratios of different kinds of white blood cells.
The CMP measures things like kidney and liver function, blood sugar, electrolytes and different protein levels.
If the situation calls for it, we will check specific “cancer markers” in the blood for various kinds of cancer. Unfortunately, there are markers for only a few kinds of cancers. These tests are used more as a measure of treatment progress and some of them can be used as a screening test for cancer.
The Nagalase test can be used as a screening and progress marker test. It is performed at the start of treatment and then rechecked at regular intervals.
The cancer Greek test is now available for more extensive and specific testing.
CA15-3 (Cancer Antigen 15-3) is a tumor marker used to monitor certain cancers, especially breast cancer. It is found on the surface of many types of cancer cells and shed into the blood stream. It is used to monitor advanced, i.e. metastatic, cancer.
Both CA27.29 and CA15-3 may be elevated in patients with benign ovarian cysts, benign breast disease, and benign liver disease. Elevations may also be seen in cirrhosis, sarcoidosis and lupus.
CA27.29 may be elevated in non-breast malignancies including colon, stomach, pancreas, prostate and lung.
CEA (Carcino Embryonic Antigen) is elevated in colon, rectal, pancreas, breast ovary and lung cancer.
CA125 is elevated in patients who have ovarian cancer.
As a patient improves and shows signs of stability, the frequency of these tests can be extended for greater and greater time periods depending on the individual circumstances.
The profile consists of 7 different tests. They are HCG (human chorionic gonadotropin), both serum and urine, PHI (phosphohexose isomerase enzyme), CEA (carcinoembryonic antigen), GGTP (a liver test), TSH (a thyroid test), and DHEA-S (an adrenal hormone).
The uniqueness of the Cancer Profile is that it combines a number of tests which, by themselves, might not be indicative enough, but together provide and impressive level of accuracy and precision.
While numerous studies have confirmed that HCG levels are elevated if there are cancer cells in the body, it may be present in super-low quantities that cannot be detected. Therefore, the Cancer Profile includes other tumor markers as well. In other words, what one test may miss, the others will usually detect.
In one study during its development, the tumor marker CEA proved to be sensitive in cases of metastasized bone cancer, while PHI was elevated in cancers of other organs. However, when CEA and PHI were combined, overall sensitivity was increased considerably.
By combining all these tests, the results provide an impressive level of accuracy and precision. It has been determined to have an overall accuracy of 87-97%!
The other thing that is remarkable about this battery of tests is that it is excellent not only for early detection, but also for laboratory follow-up and monitoring disease reduction or progression during treatment.
All this is done without the use of radiation so monitoring of progress can safely be done far more frequently than during conventional treatment.
The tests can also be important to establish a benchmark prior to surgery. With a retest later, one can determine if the surgery has removed the whole tumor.
For example, a study in the Journal of Tumor Marker Oncology in 1992 reported that men who had had their diseased prostates removed had distinctly lower levels of both PSA and HCG, compared to those patients with tumors remaining. Clearly, lower levels of these markers indicate a procedure’s effectiveness.
The markers may also serve as a warning signal of the prospect for renewed problems.
The Cancer Profile has proven itself useful in helping to move past the era of toxic cancer screening and treatment.
The IvyGene test can provide additional insight and is supplementary to other standard of care diagnostics. It provides a non-invasive option to aid in the following:
Note: The IvyGene test is not classified as a screening test.
The IvyGene® test is an adjunct clinical test that is intended to be based on the independent medical judgement of the ordering physician in conjunction with the patient’s complete medical history and the results of standard of care testing. The IvyGene® Test has been validated with four (4) cancer tissues of origin: breast, colon, liver and lung cancers. The presence of other cancer types may also result in an elevated IvyGene® Score. A large-scale clinical trial to demonstrate the efficacy of the IvyGene® Test as a cancer screening test has not been conducted. Cancer screening is not an approved utility of the IvyGene® test.
IvyGene has been commercially available since January 2018.
For commonly asked questions: https://www.ivygenelabs.com/frequently-asked-questions/
Reno Integrative Medical Center
6110 Plumas St. Ste. B, Reno, Nevada 89519
Phone: 775- 829-1009 1-800-994-1009